Compare Gilead Sciences, Inc. (GILD) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tidewater Inc — how do they compare? Gilead Sciences, Inc. trades at $132.77 (market cap $163.51B), while Tidewater Inc trades at $75.81 (market cap $3.72B). The key difference: Gilead Sciences, Inc. is far larger — about 44× Tidewater Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| GILD | TDW | |
|---|---|---|
Market Cap | $163.51B | $3.72B |
Sector | Health | Utilities |
52-Week High | $155.80 | $91.12 |
52-Week Low | $108.22 | $46.32 |
Enterprise Value | $178.05B | $3.83B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Tidewater (TDW) trades at $75.90, up 2.61% with a bullish technical signal despite recent earnings misses. The company maintains strong profitability with 22.16% net margins and 24.03% ROE, though Q1 2026 earnings of $0.12 missed expectations. Recent news includes FTAI Infrastructure's acquisition of Tidewater Logistics, potentially restructuring operations. Valuation appears reasonable with P/E of 12.63 and EV/EBITDA of 9.33.
Outlook remains mixed with analyst consensus leaning hold (61.54%) amid earnings volatility. The stock offers value fundamentals but faces execution risks after recent misses. Key catalysts include Q2 2026 earnings and integration of recent acquisitions, while risks include energy sector volatility and competitive pressures in offshore services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
